ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML is successfully treated with the BCR-ABL tyrosine kinase inhibitor imatinib (Gleevec, STI-571), which is widely appreciated as the paradigm for targeted therapy [3].